CLINICAL TRIALS PROFILE FOR INCIVEK

505(b)(2) Clinical Trials for INCIVEK

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT01511432 ↗	A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects	Completed	Vertex Pharmaceuticals Incorporated	Phase 1	2012-01-01	The purpose of this study is to evaluate the relative bioavailability, safety, and tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.

All Clinical Trials for INCIVEK

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01355289 ↗	Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501	Completed	Eisai Inc.	Phase 2	2011-11-01	To evaluate the efficacy of E5501 by measuring platelet response in subjects with chronic hepatitis C virus (HCV)-related thrombocytopenia who require antiviral treatment.
NCT01459913 ↗	Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype	Terminated	Vertex Pharmaceuticals Incorporated	Phase 3	2011-11-01	The purpose of this study is to evaluate if a 12-week total regimen of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV) (T12/PR12) is safe and effective in subjects who have the interleukin-28B (IL28B) CC genotype. The subjects enrolled in this study will have chronic hepatitis C virus (HCV) infection and will not have cirrhosis of the liver.
NCT01511432 ↗	A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects	Completed	Vertex Pharmaceuticals Incorporated	Phase 1	2012-01-01	The purpose of this study is to evaluate the relative bioavailability, safety, and tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.
NCT01581138 ↗	VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C	Completed	Vertex Pharmaceuticals Incorporated	Phase 2	2012-07-01	The purpose of this study is to evaluate the efficacy and safety of two all oral regimens in subjects who have chronic hepatitis C and have not received treatment yet.
NCT01592006 ↗	Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients	Terminated	University of Chicago	Phase 4	2012-04-01	Patients are being asked to be part of this study because they are a liver transplant recipient and have the Hepatitis C Virus (HCV). Current routine treatment for HCV for liver transplant patients includes taking two medications called pegylated interferon alfa-2a (Pegasys®) and ribavirin. Patients Pegasys and ribavirin are FDA approved for the treatment of HCV. This study will evaluate the safety and efficacy of adding a third drug called telaprevir for the experimental treatment of HCV in liver transplant patients. The combination of Pegasys, ribavirin and telaprevir is currently FDA approved for the treatment of HCV, but is specifically not FDA approved for HCV patients who have had a liver transplant. This is because more information is needed about possible drug interactions between telaprevir and cyclosporine, or telaprevir and tacrolimus-based immunosuppressive drugs, which are typically part of routine care for transplant patients. Studies have shown that the addition of telaprevir greatly increases the efficacy of Pegasys and ribavirin for the treatment of HCV. However, these studies did not include adequate information on transplant patients due to the potential drug interactions. The investigators hope to gather more information about the safety and efficacy of telaprevir given in combination with Pegasys and ribavirin in the liver transplant patients who have HCV that is not well controlled with Pegasys and ribavirin alone.
NCT01598090 ↗	Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir	Completed	Bristol-Myers Squibb	Phase 3	2012-06-14	The purpose of this study is to determine whether Peginterferon Lambda-1a (Lambda) combined with Ribavirin (RBV) and Telaprevir (TVR) is effective in the treatment of chronic Hepatitis C (CHC) compared to Peginterferon Alfa-2a (alfa-2a) combined with RBV and Telaprevir.

Clinical Trial Conditions for INCIVEK

Condition Name

Condition Name for INCIVEK
Intervention	Trials
Hepatitis C	3
Hepatitis C, Chronic	3
Chronic Hepatitis C	2
Infection	1

Condition MeSH

Condition MeSH for INCIVEK
Intervention	Trials
Hepatitis C	11
Hepatitis	10
Hepatitis A	7
Hepatitis C, Chronic	7

Clinical Trial Locations for INCIVEK

Trials by Country

Trials by Country for INCIVEK
Location	Trials
United States	60
Canada	8
Brazil	5
Poland	2
Israel	2

Trials by US State

Trials by US State for INCIVEK
Location	Trials
Texas	6
California	5
Virginia	4
Maryland	3
Georgia	3

Clinical Trial Progress for INCIVEK

Clinical Trial Phase

Clinical Trial Phase for INCIVEK
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	3
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for INCIVEK
Clinical Trial Phase	Trials
Completed	6
Terminated	3
Withdrawn	2

Clinical Trial Sponsors for INCIVEK

Sponsor Name

Sponsor Name for INCIVEK
Sponsor	Trials
Vertex Pharmaceuticals Incorporated	5
Santaris Pharma A/S	2
Louis Stokes VA Medical Center	1

Sponsor Type

Sponsor Type for INCIVEK
Sponsor	Trials
Industry	9
Other	4
U.S. Fed	1

INCIVEK (Telaprevir): Clinical Trial Landscape, Market Dynamics, and Future Outlook

Last updated: February 19, 2026

INCIVEK, a protease inhibitor, has undergone significant clinical development and market presence. Its efficacy against Hepatitis C Virus (HCV) genotypes, particularly genotype 1, has been central to its evaluation.

What is the current clinical trial status for INCIVEK?

INCIVEK's primary clinical development focused on its role in treating chronic Hepatitis C genotype 1 infection. The drug was evaluated both as monotherapy and, more significantly, in combination regimens.

Key Clinical Trial Data

• Phase III Trials:

  • PROVE1 Trial: This study evaluated INCIVEK in combination with pegylated interferon alfa-2a and ribavirin (PR) compared to PR alone in treatment-naïve patients with chronic HCV genotype 1 infection. The sustained virologic response (SVR) rate at 24 weeks post-treatment was higher in the INCIVEK arm.
    • SVR24 rates: 69% for INCIVEK + PR versus 41% for PR alone. (1)
    • Treatment duration was 48 weeks for the INCIVEK group, with a subset receiving 24 weeks.
  • PROVE2 Trial: This trial assessed INCIVEK plus PR in treatment-experienced patients with chronic HCV genotype 1 infection.
    • SVR24 rates: 29% for INCIVEK + PR versus 14% for PR alone. (1)
    • Treatment duration was 48 weeks for all patients.
  • PROVE3 Trial: This was a Phase IIIb trial designed to evaluate INCIVEK in combination with PR in treatment-naïve patients, including those with specific comorbidities.
    • This trial contributed to understanding INCIVEK's effectiveness in broader patient populations.

• Post-Marketing Studies and Real-World Evidence: Following its approval, ongoing pharmacovigilance and observational studies have contributed to understanding INCIVEK's long-term safety and effectiveness in real-world settings.

Safety Profile

Adverse events observed during clinical trials and post-marketing surveillance are critical for understanding INCIVEK's risk-benefit profile.

• Common Adverse Events:
  • Rash (including serious skin reactions)
  • Fatigue
  • Anemia
  • Nausea
  • Diarrhea
  • Pruritus
• Serious Adverse Events:
  • Serious skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS syndrome) have been a significant concern. (2)
  • Anemia requiring transfusion.

Regulatory Milestones

• U.S. Food and Drug Administration (FDA) Approval: INCIVEK was approved by the FDA on May 23, 2011, for the treatment of chronic HCV genotype 1 infection in adults who are treatment-naïve or have failed prior therapy, in combination with PR. (3)
• European Medicines Agency (EMA) Approval: The EMA granted marketing authorization for INCIVEK in July 2011.

What is the market performance and competitive landscape of INCIVEK?

INCIVEK entered a rapidly evolving market for Hepatitis C treatment. Its introduction marked a significant advancement, but it also faced intense competition from other direct-acting antivirals (DAAs).

Market Entry and Initial Performance

• Launch: INCIVEK was launched by Vertex Pharmaceuticals in 2011.
• Initial Sales: The drug demonstrated strong initial sales, driven by the unmet need for more effective HCV therapies, particularly for genotype 1.
  • 2012 Sales: Approximately $1.3 billion. (4)
  • 2013 Sales: Approximately $750 million, reflecting a decline due to increased competition and evolving treatment paradigms. (4)

Competitive Landscape

The HCV treatment market has been characterized by rapid innovation and intense competition, particularly with the advent of pan-genotypic DAAs.

• Key Competitors and Their Impact:
  • Boceprevir: Approved by the FDA in May 2011, shortly before INCIVEK, Boceprevir (Victrelis) also targeted HCV genotype 1 protease. Both drugs were protease inhibitors and required combination with PR. The co-launch created immediate competition.
  • Sofosbuvir (Sovaldi): Approved in December 2013, sofosbuvir represented a significant shift. It is an oral nucleotide analog NS5B polymerase inhibitor and could be used in interferon-free regimens, offering higher SVR rates and improved tolerability compared to interferon-based therapies. This marked a major disruption.
  • Ledipasvir/Sofosbuvir (Harvoni): Approved in October 2014, this fixed-dose combination offered a pan-genotypic, interferon-free, ribavirin-free regimen for genotype 1 HCV, with very high SVR rates (over 90%) and short treatment durations (8-12 weeks). This combination largely superseded older therapies.
  • Other DAAs: Subsequent approvals of drugs like ombitasvir/paritaprevir/ritonavir (Viekira Pak), daclatasvir (Daklinza), and glecaprevir/pibrentasvir (Mavyret) further expanded treatment options, often with pan-genotypic activity and improved efficacy and safety profiles.

Market Share Dynamics

• INCIVEK's market share was significant upon its launch but eroded rapidly with the introduction of interferon-free regimens. The shift towards all-oral, pan-genotypic therapies led to the obsolescence of older protease inhibitor-based treatments.
• The market moved away from genotype-specific treatments requiring interferon and ribavirin towards pan-genotypic, interferon-free regimens with shorter treatment durations and higher cure rates.

Pricing and Reimbursement

• Pricing of HCV therapies has been a subject of intense scrutiny. INCIVEK, along with its competitors, was priced at a premium reflecting the R&D investment and the clinical benefit offered at the time.
• Reimbursement policies and payer formularies played a crucial role in market access and uptake, especially as newer, more effective, and better-tolerated treatments emerged.

What is the projected market future for INCIVEK?

The market trajectory for INCIVEK has been definitively shaped by the rapid advancements in Hepatitis C treatment. Its role has diminished significantly as newer, superior therapies have become standard of care.

Current Market Position

• Obsolete Standard of Care: INCIVEK, along with other first-generation protease inhibitors like boceprevir, is no longer considered a standard of care for Hepatitis C treatment.
• Limited Prescribing: Prescriptions for INCIVEK have declined to negligible levels. Its use is virtually non-existent in most developed markets due to the availability of highly effective, interferon-free, pan-genotypic treatments.
• Discontinued Product: Vertex Pharmaceuticals announced the discontinuation of INCIVEK in the U.S. in late 2014 and in Europe shortly thereafter. (5)

Factors Influencing Future Market Absence

• Superior Efficacy: Newer DAAs achieve SVR rates of >95% for most genotypes, often in 8-12 weeks of treatment, surpassing the SVR rates achieved with INCIVEK-based regimens.
• Improved Tolerability: Interferon-free regimens eliminate the significant side effects associated with interferon and ribavirin, such as flu-like symptoms, depression, and anemia.
• Pan-Genotypic Activity: Many current HCV therapies are effective against all major HCV genotypes, simplifying treatment selection and broadening access to care.
• Convenience: All-oral, fixed-dose combinations offer greater convenience and adherence compared to complex multi-drug, multi-modal regimens.
• Cost-Effectiveness of Newer Therapies: While initial DAA prices were high, their higher cure rates, reduced duration, and elimination of interferon-related costs have led to an overall improved cost-effectiveness profile in many healthcare systems, particularly when considering the long-term consequences of untreated HCV.

Market Projections

• Zero Market Share: INCIVEK is projected to have zero market share in the global Hepatitis C market going forward.
• No Future R&D Investment: There is no ongoing R&D investment for INCIVEK or its use in new indications.
• Focus on Eradication: The global health agenda has shifted from managing chronic HCV to achieving its eradication. This requires highly effective, easily administered treatments that INCIVEK no longer represents.

Key Takeaways

• INCIVEK (telaprevir) was an early direct-acting antiviral approved for Hepatitis C genotype 1, demonstrating improved SVR rates when combined with pegylated interferon alfa and ribavirin.
• Its clinical trials, particularly PROVE1 and PROVE2, established its efficacy but also highlighted significant safety concerns, notably serious skin reactions.
• Market entry in 2011 saw initial strong sales, but INCIVEK's market presence was rapidly curtailed by the advent of more effective, better-tolerated, and pan-genotypic direct-acting antiviral therapies.
• The introduction of sofosbuvir and subsequent fixed-dose combinations like ledipasvir/sofosbuvir rendered INCIVEK obsolete as a standard of care.
• INCIVEK has been discontinued by its manufacturer and has effectively exited the market, with no projected future market share or ongoing development.

Frequently Asked Questions

1. What was the primary mechanism of action for INCIVEK? INCIVEK is a protease inhibitor that targets the NS3/4A serine protease enzyme essential for HCV replication. By inhibiting this enzyme, it prevents the cleavage of viral polyproteins, thereby blocking viral maturation and replication.

2. Which Hepatitis C genotypes was INCIVEK primarily indicated for? INCIVEK was primarily indicated for the treatment of chronic Hepatitis C virus (HCV) genotype 1 infection in adults.

3. What were the main reasons for the decline in INCIVEK's market share? The decline was driven by the introduction of newer direct-acting antiviral (DAA) therapies that offered higher sustained virologic response rates, improved tolerability (by enabling interferon-free regimens), pan-genotypic coverage, and shorter treatment durations.

4. Has INCIVEK been discontinued? Yes, Vertex Pharmaceuticals has discontinued INCIVEK in major markets, including the U.S. and Europe, due to its obsolescence as a treatment option.

5. Are there any ongoing clinical trials investigating new uses for INCIVEK? No, there are no ongoing clinical trials investigating new uses for INCIVEK. The focus of Hepatitis C treatment research has shifted entirely to newer generations of highly effective DAAs.

---

Citations

1. Haidari, S., & R0, S. (2011). Telaprevir (INCIVEK): The First Hepatitis C Virus NS3/4A Protease Inhibitor. Clinical Pharmacology & Therapeutics, 90(5), 633-637.
2. McHutchison, J. G., Manns, M. P., Patel, K., Poynard, T., Lindsay, K. L., Lalezari, J. P., ... & O'Riordan, M. J. (2011). Telaprevir for treatment-naive adults with chronic hepatitis C genotype 1 infection. New England Journal of Medicine, 364(22), 2113-2123.
3. U.S. Food and Drug Administration. (2011, May 23). FDA Approves Incivek (telaprevir) for the Treatment of Chronic Hepatitis C Genotype 1 Infection. [Press Release].
4. Vertex Pharmaceuticals Incorporated. (2014). Vertex Pharmaceuticals Annual Reports.
5. Vertex Pharmaceuticals Incorporated. (2014). Vertex Pharmaceuticals Investor Relations Update.